chore: daily update 2026-09-11

sources/literature.md

@@ -14,6 +14,12 @@ timestamp: 2026-08-27T18:25:00Z
 
 ## Last 30 days of deep reads (mtime descending)
 
+### 2026-09-10 (HGSC ovarian-cancer PDO combination-therapy deep-read — non-vendor, PMC gold OA)
+
+| DOI | Vendor | Application | Title (short) | Vault path |
+| --- | --- | --- | --- | --- |
+| `10.1080/15384047.2025.2611602` | **none — 0 product mentions** (spheroid = ULA static plate; organoid = Cultrex BME; no bioreactor/spinner) | HGSC patient-ascites iOvCa lines (n=6) as spheroids + organoids; carboplatin ± olaparib/niraparib direct vs sequential | Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG (2026) **Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids** (Cancer Biol Ther 27(1):2611602; Western University; PMID 41520277; PMC12795296 gold OA; Wiki.js 1787) — direct combination did NOT exceed carboplatin alone (no additivity/synergy); only exception = BRCA1-mutant iOvCa195 organoids benefit when PARPi given FIRST; niraparib more potent than olaparib except iOvCa256 (27.16 vs 18.09 µM); RAD51 foci functional HRD validation. Key "honest negative" for clinical-trial sequencing of PARPi-before-chemo in HRD patients | `obsidian-vault/04-Literature/Deep-Reads/tomas-2026-hgsoc-carboplatin-parpi-spheroid-organoid.md` |
+
 ### 2026-08-31 (5-paper CelVivo-anchored single-shot LDR burst — NEW `CelVivo/` capital-V subfolder)
 
 | DOI | Vendor | Application | Title (short) | Vault path |